Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

You Can Mix Up Your Daily Steps And Still Lower Risk of Death, Research Shows : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-13

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of six claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 3 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredA new study in the British Journal of Sports Medicine analyzed records from more than 64,000 middle-aged individuals in a large health research database, following them for an average of eight years.View evidenceHide evidence

As statedmore than 64,000 participants; average follow-up eight years

Why this verdict

The abstract-level profile supports a UK Biobank wrist-accelerometer prospective cohort analysis with 64,743 participants and mean age 61.5 years, which is consistent with 'more than 64,000' middle-aged/older adults. However, the abstract profile explicitly says follow-up duration is not provided, so the stated average follow-up of eight years cannot be verified at this evidence depth.

1

Study evidence

In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.

“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
Claim 2 of 6Not coveredThe researchers said a peak 30-minute cadence of around 90-100 steps per minute, averaged across the 30 highest-cadence minutes of the day, was a useful health target.View evidenceHide evidence

As stated90-100 steps per minute

Why this verdict

The abstract supports that PK30 is defined as the average cadence during the highest 30 minutes of the day, and it reports lower mortality patterns around 90 steps/min and a nadir around 100 steps/min in the 7500-10,000 steps/day group. However, the abstract-level profile does not verify that the researchers presented 90-100 steps/min as a 'useful health target'; that recommendation-like framing would require full-text evidence.

1

Study evidence

In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.

“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
Claim 3 of 6Not coveredThe article notes that the study was observational, so it cannot prove cause and effect, and that step activity was only recorded for part of the study period and may have changed over time.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the observational-design caveat and residual-confounding concern. It does not verify the specific caveat that step activity was recorded only for part of the study period and may have changed over time, so the full claim cannot be verified at abstract depth.

1

Study evidence

In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.

“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
Claim 4 of 6SupportedThe study found that people do not have to hit 10,000 steps a day to see benefits from walking.View evidenceHide evidence

As stated10,000 steps a day

Why this verdict

The abstract reports lower all-cause mortality associations in sub-10,000-step strata, including <5000 steps/day at higher PK30 and 5000-7500 steps/day at lower PK30, and the lowest-risk step-count group was 7500-10,000 steps/day. Framed as an association that benefits may occur below 10,000 steps/day, this is supported. The headline wording is somewhat simplified, but the supplied presentation also notes the observational caveat.

1

Study evidence

In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.

“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
Claim 5 of 6SupportedA variety of step counts and intensities were associated with lower mortality risk, including similar and substantial reductions for walking fewer than 5,000 steps a day at a brisk pace and walking 5,000-7,500 steps a day at a slower pace.View evidenceHide evidence

As statedaround 80 steps per minute; around 60 steps per minute

Why this verdict

The abstract supports this comparison: in the <5000 steps/day stratum, PK30 of 80 steps/min was associated with lower all-cause mortality (HR 0.72, 95% CI 0.54-0.97), and in the 5000-7500 steps/day stratum, PK30 of 60 steps/min was associated with a similar lower risk (HR 0.70, 95% CI 0.58-0.86).

1

Study evidence

In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.

“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
Claim 6 of 6SupportedTaking pace out of the equation, 7,500-10,000 steps per day was linked to the lowest mortality risk.View evidenceHide evidence

As stated7,500-10,000 steps per day

Why this verdict

The abstract-level profile states that the 7500-10,000 steps/day group had the lowest all-cause mortality risk overall, with a U-shaped PK30-mortality pattern and nadir near 100 steps/min. The story's associational wording is consistent with that evidence.

1

Study evidence

In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.

“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Uncertainty in some subgroup estimates, including wide confidence intervals that include the null for some 90 steps/min comparisons.

    The abstract profile notes that some subgroup estimates, such as <5000 steps/day at 90 steps/min, have wide confidence intervals crossing the null. The story presentation does not indicate this uncertainty when discussing brisker walking or 90-100 steps/min targets.

    From Prospective cohort analysis of UK Biobank wrist-worn accelerometer subsample

5 things the story did carry across
  • Primary paper finding: joint dose-response associations of peak 30-minute cadence and daily step-count categories with all-cause mortality in the UK Biobank accelerometer cohort.
  • Sample and exposure framework: 64,743 UK Biobank accelerometer participants; PK30 cadence and daily step categories of <5000, 5000-7500, 7500-10,000, and >10,000 steps/day.
  • Secondary paper finding: cardiovascular disease mortality analyses showed dose-response patterns similar to all-cause mortality, using Fine and Gray competing-risks models.
  • Key quantitative all-cause mortality examples: <5000 steps/day with PK30 80 steps/min HR 0.72; 5000-7500 steps/day with PK30 60 steps/min HR 0.70; 7500-10,000 steps/day lowest overall risk with nadir near 100 steps/min.
  • Observational design and residual confounding limitation.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the joint dose–response association of stepping intensity (peak 30-min cadence, PK30) and daily step counts with all-cause mortality in UK Biobank accelerometer participants.Prospective cohort analysis of UK Biobank wrist-worn accelerometer subsampleExpand

In plain English

Prospective cohort analysis in the UK Biobank wrist-worn accelerometer subsample estimating joint dose–response associations of stepping intensity (peak 30-min cadence, PK30) and daily step-count categories with all-cause mortality using multivariable-adjusted Cox models (n=64,743; 1,697 deaths).

Key findings

  • In the UK Biobank accelerometer subsample (n=64,743; 1,697 deaths), higher stepping intensity (PK30) was associated with lower all-cause mortality within lower daily step-count strata.
  • Examples of reported associations: in participants with <5000 steps/day, PK30 of 80 steps/min vs reference: HR 0.72 (95% CI 0.54–0.97); in 5000–7500 steps/day, PK30 of 60 steps/min vs reference: HR 0.70 (95% CI 0.58–0.86).HR 0.72 (95% CI 0.54–0.97); HR 0.70 (95% CI 0.58–0.86)
“This prospective cohort study included the UK Biobank wrist-worn accelerometers subsample.”
What this piece can’t prove
  • Observational design—associations may be affected by residual confounding and selection into the accelerometer subsample.

2 further details could not be confirmed from the summary.

2secondary dataEstimate the joint dose–response association of stepping intensity (PK30) and daily step counts with cardiovascular disease (CVD) mortality in the same cohort, accounting for competing risks.Prospective cohort; competing-risks survival analysisExpand

In plain English

In the UK Biobank wrist-accelerometer prospective subsample, the authors report that the joint dose–response association of stepping intensity (peak 30-min cadence, PK30) and categorized daily step counts with cardiovascular disease (CVD) mortality showed similar dose–response patterns to those observed for all-cause mortality, based on multivariable-adjusted Fine and Gray competing-risks models. Numerical effect estimates for CVD mortality are not reported in the abstract.

Key findings

  • CVD mortality analyses (Fine and Gray competing-risks models) showed dose–response patterns similar to those reported for all-cause mortality.
“We examined the multivariable-adjusted dose-response associations of PK30 and step counts with ACM/CVD mortality using Cox proportional and Fine and Gray subdistribution hazard models, respectively.”
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Review of "The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis"

2023 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.